HLB Subsidiaries Showcased Cancer Research Progress at AACR 2024

· HLB Therapeutics Presents Promising Results from Phase 2 trial
· HLB Life Sciences Presents Novel Drug for Colorectal Cancer

HLB Group Showcased Cancer Research Progress at AACR 2024 (Image: IT Times)

SEOUL, South Korea, April 28, 2024 (IT Times) - HLB Group, a leading Korean biopharmaceutical company's subsidiaries, HLB Therapeutics, HLB Life Sciences, and Elevar Therapeutics, presented its latest cancer research findings at the American Association of Cancer Research (AACR) 2024 annual meeting, held in San Diego, California, from April 5 to 10.

HLB Therapeutics Presents Promising Results from Phase 2 trial

HLB Therapeutics presented data from its Phase 2 clinical trial of OKN-007 combined with temozolomide, a novel drug candidate for cancer treatment. The trial exceeded its primary endpoint, demonstrating a patient survival rate of 75.8% at 6 months, exceeding the target of 60%. In addition, the study showed a median overall survival (mOS) of 9.3 months.

HLB Life Sciences Presents Novel Drug for Colorectal Cancer

HLB Life Sciences' R&D team presented its findings on HLS-22001, a drug candidate designed to target colorectal cancer cells that have developed resistance to first-line chemotherapy. The research demonstrated HLS-22001's potential in inhibiting cancer cell proliferation in such cases.

Elevar Therapeutics Presented Research on Targeted Therapies

Elevar Therapeutics, HLB's US subsidiary, contributed to the conference by publishing a research paper on its targeted anti-cancer drug, rivoceranib. The paper discusses the drug's mechanism of action and potential applications.

Sharing Expertise and Fostering Collaboration

"We are excited to share our advances in drug development with leading cancer researchers and major pharmaceutical companies at AACR 2024," said Shim Kyung-jae, Senior Vice President of External Affairs at HLB Group. "This is a valuable opportunity to collaborate and accelerate progress in the fight against cancer. For rivoceranib in particular, we are committed to ongoing research to unlock its full potential and explore broader treatment applications in the future."

IT타임스 YoungHa Kim (yhkim@ittimes.com)

출처 IT타임스 : https://www.ittimes.com/news/articleView.html?idxno=31484

HLB Subsidiaries Showcased Cancer Research Progress at AACR 2024 - IT타임스